Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.
Recor Medical's Paradise Ultrasound Renal Denervation System is the first medical device approved for the treatment of hypertension in Japan. It first gained FDA approval back in 2023.
Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%.
The company describes Vivid Pioneer as its “most advanced, ultra-premium and adaptive cardiovascular ultrasound system yet.” It includes new and improved AI capabilities and a compact design that is still fully functional in tight workspaces.
Rad Partners "firmly" denied the allegations, which mirror a similar complaint from Aetna, contending it plans to "vigorously defend against these claims" in court.
After losing a court battle with the Fortune 500 company last year, Jeffrey C. Allard, MD, and attorneys are homing in on an attorney's faulty credentials, claiming she "poisoned" the proceedings.
Vital Imaging Diagnostic Centers recently alerted patients about the apparent cyberattack with an unauthorized party likely gaining access to private health information.
Vital Imaging Diagnostic Centers recently alerted patients about the apparent cyberattack with an unauthorized party likely gaining access to private health information.
A new analysis published in Artificial Intelligence in Medicine argues that education tools are failing to show clinicians how to make use of new technologies, calling into question the benefit of rapid adoption.
Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.
Recor Medical's Paradise Ultrasound Renal Denervation System is the first medical device approved for the treatment of hypertension in Japan. It first gained FDA approval back in 2023.
Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%.
